Life (Nov 2023)

Temporal Trends in Diagnostic Hemodynamics and Survival of Patients with Pulmonary Hypertension: A Single-Center Study

  • Georgios E. Papadopoulos,
  • Alexandra Arvanitaki,
  • Eleftherios Markidis,
  • Sophia Anastasia Mouratoglou,
  • Ioannis T. Farmakis,
  • Panagiotis Gourgiotis,
  • Thomas Chrysochoidis Trantas,
  • Christos Feloukidis,
  • Antonios Kouparanis,
  • Matthaios Didagelos,
  • Vasilis Grosomanidis,
  • Antonios Ziakas,
  • George Giannakoulas

DOI
https://doi.org/10.3390/life13112225
Journal volume & issue
Vol. 13, no. 11
p. 2225

Abstract

Read online

Advances in the diagnosis and treatment of pulmonary hypertension (PH) have gradually improved the disease course. This retrospective cohort study aims to explore the diagnostic hemodynamic profile and survival of PH patients and their temporal changes, as well as investigate potential prognostic factors. Overall, 257 adult patients were diagnosed with PH following right heart catheterization (RHC) from January 2008 to June 2023 according to the hemodynamic cut-off values proposed by the corresponding ESC/ERS guidelines at the time RHC was performed. Of these patients, 46.3% were Group 1, 17.8% Group 2, 14.0% Group 3, 18.0% Group 4, and 3.0% Group 5 PH. Temporal improvement in both diagnostic hemodynamic profile and survival of patients with PH and pulmonary arterial hypertension (PAH) was identified after 2013. Survival analysis demonstrated 5-year survival rates of 65% in Group 1 PH (90.3% in idiopathic PAH) and 77% in Group 4 PH. PAH patients being at low risk at diagnosis presented a similar 1-year all-cause mortality rate (12.4%) with high-risk ones (12.8%), primarily due to non-PH-related causes of death (62%), while high-risk patients died mostly due to PH (67%). The observed improvements in diagnostic hemodynamic profiles and overall survival highlight the importance of timely diagnosis and successful treatment strategies in PH.

Keywords